Medical Devices & Diagnostics Industry:
2010 Market Outlook

Expert analysis of recent history, and a look forward at what it all means for the future of devices and diagnostics

Previously published in IN VIVO, Start-Up, and Medtech Insight


The most significant period of change for the medtech industry is upon us, and no one in the business can afford to misunderstand or ignore the coming revolution. This eye-opening forecast of the political, regulatory, economic, and scientific outlook for medical technology will soon be mandatory reading everywhere, from the laboratory to the boardroom to the corner office.

 

Prepared by Elsevier Business Intelligence’s expert analysts, this 90-page Special Report answers all the business-critical questions you may not have thought of:

  • Why won’t healthcare reform benefit the device industry in the same way it will for biopharma?

  • Why should I believe that regulatory reform is really going to happen now, when it’s been talked about for years?

  • Where are the investor dollars flowing – and who is doing the pouring?

  • Which unexpected therapeutic areas – besides the obvious cardiovascular and orthopedics – are going to be hot?

 

The device tax

Both segments of the healthcare industry have been hit with new taxes to help fund reform. But unlike biopharma companies, which can look forward to being rewarded with millions of new customers for their products, devices are more often used in acute or chronic care settings where patients receive care regardless of their insurance status. Worse, small and mid-sized medtech companies, where device innovation thrives, will be hit hardest. And finally, other aspects of healthcare reform may be even more painful than the tax.

 

Raising the bar for 510(k)

There’s been talk of making the 510(k) process more rigorous – and expensive – for years. Now, however, rather than the bottom of the food chain, the new sheriff at the FDA and her deputies are the ones doing the talking, and this time analysts are bracing for the worst to actually happen. This threatens the traditional device innovation model and the underpinnings of the entire industry. However, analysts also see a dim but perceivable silver lining in what’s to come.

 

IPO, M&A, or DOA?

Exits of any kind dried up in 2009. Device companies couldn’t find the money, and venture capitalists who did spend money, were finding their returns hardly worth it. In this report, our experts not only identify the winners and losers of 2009, but also the future trends in financing; the most promising therapeutic areas; which innovators, acquirers, and investors are likely to come out on top in 2010; and which factors will impact each of these groups.

 

In what direction is technology moving?

Everyone knows that cardiovascular and orthopedics will continue to be strong performers for device companies. What many don’t know yet is the market outlook for lesser-known technologies like intraocular lenses and NOTES. Also included in this report are market forecasts for diagnostics, cardiovascular, peripheral vascular, orthopedics, neurovascular, metabolic, and hospital markets.


Ordinarily, to read all of the content included in this Special Report, you would need to already receive IN VIVO, Start-Up, and Medtech Insight, and that would cost more than $4,500. Further, to purchase all the associated articles individually, would cost more than $2,500. We are offering this extremely useful Special Report for just $349 – about the same price you’d pay for only four single articles.